Will the disease develop crazily after discontinuing Upatinib/Refu?

Upadacitinib is a selective JAK1 inhibitor developed by AbbVie, with the trade name Rinvoq. It is mainly used to treat rheumatoid arthritis (RA), active psoriatic arthritis (PA), atopic dermatitis (AD), ulcerative colitis (UC), ankylosing spondylitis and other autoimmune diseases. As a new generation of oral small molecule targeted drug, upadatinib can precisely inhibit the JAK-STAT signaling pathway, reduce the excessive release of inflammatory factors, and fundamentally control the inflammatory response. For many patients who suffer from long-term joint swelling and pain or skin inflammation, upadatinib is usually effective and has a rapid onset of action, making it an important choice for many people to maintain stable conditions.

However, many patients are most concerned about whether their condition will "rebound" or "progress crazily" after stopping the drug. In fact, according to overseas pharmaceutical experts and long-term treatment experience, upadatinib works by continuously suppressing immune signals to maintain disease control. Once the drug is stopped, inflammatory factors in the body may gradually return to their original active state. Therefore, some patients may experience an aggravation of the disease or recurrence of symptoms after stopping the drug.

This situation is not the so-called "rebound exacerbation", but is caused by the resumption of activity of the disease itself after the drug effect has ceased. Especially for patients with rheumatoid arthritis and atopic dermatitis, the inflammatory reaction often gradually recovers within weeks to months after stopping the drug, manifesting as symptoms such as joint pain, recurrence of rash, or worsening of itching.

Upadatinib is not a "dependence drug". The worsening of symptoms after discontinuation of the drug is a natural response to the activity of the primary disease, rather than a side effect caused by the drug. Therefore, when stopping the drug, you should follow the doctor's guidance and gradually transition or adjust to other immunomodulatory drugs according to the condition, rather than stopping suddenly.

Reference materials:https://www.rinvoq.com/